Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520549 | 0.79 | HDAC6 (0.47) | HDAC8HDAC6NPC1ALDH1A1KMT2A | |
| SCHEMBL3156503 | 0.77 | HDAC8 (0.59) | HDAC8HDAC6NPC1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL6122554 | 0.75 | HDAC8 (0.58) | HDAC8HDAC6NPC1ALDH1A1KMT2A | |
| SCHEMBL19125641 | 0.74 | DRD2 (0.56) | ALDH1A1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL2592594 | 0.74 | DRD2 (0.56) | ALDH1A1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL10762009 | 0.73 | TAAR1 (0.48) | HDAC8HDAC6NPC1ALDH1A1KMT2A | |
| SCHEMBL16641032 | 0.73 | ATM (0.54) | ALDH1A1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL28543276 | 0.71 | ALDH1A1 (0.47) | ALDH1A1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL2588682 | 0.71 | KMT2A (0.67) | ALDH1A1KMT2A | |
| SCHEMBL21896280 | 0.69 | TSHR (0.38) | ALDH1A1KMT2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | DRD4, DRD2, DRD1 | HDAC8 1875/4885HDAC6 462/4885NPC1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.